◆ NeutralRYETBGLC
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene Lab
GlobeNewswire Inc.·
Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.
Read Full Article at GlobeNewswire Inc. →